DiaBridge AB
Developing breakthrough drugs targeting DNA repair for cancer and inflammation.
Översikt
- 0
- Anställda
- ≤1t SEK
- Omsättning
- 2014
- Grundat
Nyckelbeslutsfattare
Ulrika Warpman Berglund
CEO
Ingvar Karlsson
Member of the Board
Thomas Helleday
Member of the Board
Eva Sjökvist Saers
Chairman of the board
+5 fler kontakter i Funnelfeedr
Beskrivning
Oxcia AB is a science-led Swedish biotechnology company focused on revolutionizing treatments for cancer and inflammation. The core of their innovation lies in the unique O2-DDR technology platform, which manages oxidative stress, oxidative DNA damage, and the DNA Damage Response (DDR) in cells. Thi...
Taggar
Nyckelord
Företagsinformation
- Bransch
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556979799501
Beslutsfattare
9 kontakter i FunnelfeedrUlrika Warpman Berglund
CEO
Ingvar Karlsson
Member of the Board
Thomas Helleday
Member of the Board
Eva Sjökvist Saers
Chairman of the board
Austin Smith
Chief Medical Officer
Håkan Nordlander
Head Administration and Accounting
Gustaf Eriksson
Sales and Marketing Manager
Monika Vedin
Business strategy & Communication Director
Christina Kalderén
Preclinical Director
Liknande företag
20 liknande företag i Funnelfeedr
PILA PHARMA AB
1–4 anställdaClinical stage biotech developing an oral obesity and diabetes treatment.
MyCural Therapeutics AB
10–19 anställdaDeveloping novel small molecule therapies targeting the MYC oncoprotein.
Beactica Therapeutics AB
6 anställdaPrecision medicine company developing novel therapeutics via targeted protein degradation.
Oncotech Nordic AB
0 anställdaDeveloping AI diagnostics and immunotherapy to conquer global cancer.
One-carbon Therapeutics AB
Clinical-stage biotech pioneering novel anti-cancer therapies targeting metabolism.
Utforska mer
Frågor om DiaBridge AB
Vill du se Funnelfeedr i praktiken?
Boka en gratis demo och upptäck hur Funnelfeedr hjälper dig att hitta och konvertera dina idealkunder.
Boka en demo